Please ensure Javascript is enabled for purposes of website accessibility

Home COVID-19 test brand acquired by Greenville conglomerate

Molly Hulsey //July 16, 2021//

Home COVID-19 test brand acquired by Greenville conglomerate

Molly Hulsey //July 16, 2021//

Listen to this article

Diversified Medical Healthcare, a conglomerate of four Greenville health care companies specializing in advanced molecular diagnostics, medical supplies and laboratory equipment, recently acquired the COVID-19 home testing company, RapidRona.

RapidRona test results are delivered straight to the customer in 48 hours or less, according to a news release. 

“We know that COVID-19, unfortunately, is something our population will continue to face,” Kevin Murdock, CEO and founder of Diversified Medical Healthcare, said in the news release. “As recent reports show that the new variants spread faster, cause more severe symptoms, and are causing a decrease in vaccine efficacy, the acquisition of RapidRona is our logical next step in providing necessary solutions for the future of COVID-19. We’re proud to add at-home diagnostic and wellness testing to all that we offer at Diversified Medical Healthcare.”

According to a recent Yale Medicine article cited by the release, the Delta variant is spreading 50% faster than the Alpha variant, which was 50% more contagious than the original strain of COVID-19. 

According to data cited by the press release, “1,271 of 1,528 total new infections were fully vaccinated individuals as were 23 of 27 hospitalizations and 11 out of 17 cases of severe illness.” 

Pivoting from a trend of at-home COVID-19 antigen tests, RapidRona kits provide RT-PCR tests.

“We are excited to see the technology platform in good hands advancing the consumer’s ability to proactively direct their health care from home,” Former RapidRona CEO Heather Mlodinow said in the release.

Diversified Medical Healthcare has reached one of the highest testing capacities in the nation with the capability to process more than 300,000 tests per day, according to the release. They’ve also shifted production to add in-house manufacturing of COVID-19 testing kits and reagents to combat infrastructure limitations and make testing more accessible.

 

t